Overview

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

Status:
Completed

Trial end date:
2018-12-10

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary incontinence episodes in patients with overactive bladder (OAB) and urinary incontinence whose symptoms have not been adequately managed with an anticholinergic.

Phase:

Phase 4

Details

Lead Sponsor:

Allergan

Treatments:

abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
onabotulinumtoxinA